ArticleJournal of muscle research and cell motility1998
Dethiophalloidin increases Ca2+ responsiveness of skinned cardiac muscle.
Article in Journal of muscle research and cell motility, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- Characterization of secophalloidin-induced force loss in cardiac myofibrils.Journal of muscle research and cell motility · 2009Article
- Different myofilament nearest-neighbor interactions have distinctive effects on contractile behavior.Biophysical journal · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Phalloidin, an F-actin stabilizing peptide, is known to enhance Ca2+ responsiveness in skinned cardiac muscle. Here we studied the effects of dethiophalloidin (DTPH), a phalloidin derivative which, binding much more weakly to F-actin, on skinned bovine left ventricle muscle. When added to activated skinned muscle, DTPH (15-80 micron), similarly to phalloidin, caused a rapid (within several minutes) enhancement of active force; the relative force enhancement by DTPH became greater as Ca2+ concentration was decreased. Unlike phalloidin, DTPH effects were reversible. Using a value of the force enhancement at 15 micron DTPH (76% of maximum), an apparent equilibrium constant for DTPH binding to myofilaments was estimated at about 5 micron. Force-pCa plots showed that DTPH (80 micron) brought about a 10% increase in the maximal Ca(2+)-activated force and a 0.34 pCa units increase in the Ca2+ sensitivity. Both changes are stronger than those caused by phalloidin in similar conditions (6% and 0.2 pCa units, respectively). As with phalloidin, DTPH did not change the value of the Hill coefficient in the fit tothe force-pCa curve. DTPH and phalloidin interacted as follows: (1) pre-treatment with phalloidin entirely prevented the response to DTPH, indicating the absence of any non-specific DTPH action; and (2) when added after DTPH, phalloidin decreased the force enhancement due to DTPH, reflecting a stronger effect of DTPH to increase force. In conclusion, the stabilization of F-actin structure is not a major factor in the mechanism by which phalloidin modifies contraction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.